18040dkk
0,5 %
Date:2025-06-04Time:17:20:00Latest report:Q1-2025List:Large CapTicker:BAVA
Market Cap:14 225 mdkkEnterprise Value:13 107 mdkkNet Sales:6 231 mdkkEarnings:1 321 mdkkEmployees:0ISIN:DK0015998017

Ratios

10-year key figure history for Bavarian Nordic turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Bavarian Nordic with index and moving average MA50 and MA200.

Stockprice:180,40
MA50:158,80
MA200:194,19
Price/MA200:-7,1 %
RSI (14):67,9
Price/MA50:13,6 %

Description

Bavarian Nordic is a biochemistry company. Today, the company specializes in the development, manufacture, and distribution of vaccines against infectious diseases in connection with cancer treatment. In addition, vaccines against other serious diseases such as Ebola and cervical cancer are also being developed. The largest operations are located in Europe and in the U.S. Bavarian Nordic was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Biotechnology